These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 6868908)
1. A quinazoline antifolate as inhibitor of folate metabolism in mouse L-cells. Sikora E; Grzelakowska-Sztabert B Acta Biochim Pol; 1983; 30(2):193-201. PubMed ID: 6868908 [TBL] [Abstract][Full Text] [Related]
2. Quinazoline CB 3717 and CB 3703 inhibition of folate retention and metabolism in Ehrlich ascites carcinoma cells and some organs of the host-mouse. Sikora F; Grzelakowska-Sztabert B Cancer Lett; 1984 Jul; 23(3):289-95. PubMed ID: 6744253 [TBL] [Abstract][Full Text] [Related]
3. Polyglutamation of the antifolate anticancer drug N10-propargyl-5,8-dideazafolic acid (CB 3717) in the mouse. Manteuffel-Cymborowska M; Sikora E; Grzelakowska-Sztabert B Anticancer Res; 1986; 6(4):807-12. PubMed ID: 2875688 [TBL] [Abstract][Full Text] [Related]
4. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity. Jackman AL; Kimbell R; Brown M; Brunton L; Boyle FT Anticancer Drug Des; 1995 Oct; 10(7):555-72. PubMed ID: 7495479 [TBL] [Abstract][Full Text] [Related]
5. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein. Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196 [TBL] [Abstract][Full Text] [Related]
6. The influence of folate antagonists on the metabolism of folic acid and its reduced derivatives in rat liver and kidney. Bühring U; Shin YS; Fölsch E Cancer Res; 1977 Jan; 37(1):299-304. PubMed ID: 830415 [TBL] [Abstract][Full Text] [Related]
7. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. Rhee MS; Galivan J; Wright JE; Rosowsky A Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264 [TBL] [Abstract][Full Text] [Related]
8. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201 [TBL] [Abstract][Full Text] [Related]
9. Dose dependent retention and polyglutamation of N10-propargyl-5,8-dideazafolic acid (CB 3717) in the tumour-bearing mouse. Manteuffel-Cymborowska M; Kaminska B; Grzelakowska-Sztabert B Anticancer Res; 1988; 8(4):791-6. PubMed ID: 3178167 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors. Bettio A; Honer M; Müller C; Brühlmeier M; Müller U; Schibli R; Groehn V; Schubiger AP; Ametamey SM J Nucl Med; 2006 Jul; 47(7):1153-60. PubMed ID: 16818950 [TBL] [Abstract][Full Text] [Related]
11. Uptake of folate and its analogue-amethopterin by mouse L-cells. Grzelakowska-Sztabert B Acta Biochim Pol; 1976; 23(4):309-20. PubMed ID: 1015153 [TBL] [Abstract][Full Text] [Related]
12. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626 [TBL] [Abstract][Full Text] [Related]
13. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. Temmink OH; Hoogeland MF; Fukushima M; Peters GJ Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590 [TBL] [Abstract][Full Text] [Related]
14. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Zhao R; Babani S; Gao F; Liu L; Goldman ID Clin Cancer Res; 2000 Sep; 6(9):3687-95. PubMed ID: 10999762 [TBL] [Abstract][Full Text] [Related]
15. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558 [TBL] [Abstract][Full Text] [Related]
18. Folate reductase of the amethopterin-resistant Streptococcus faecium var. durans-Ak. I. Inhibition by amethopterin and methasquin, a new quinazoline antifolate. Albrecht AM; Hutchison DJ Mol Pharmacol; 1970 Jul; 6(4):323-34. PubMed ID: 4393363 [No Abstract] [Full Text] [Related]
19. Comparison of folylderivative biosynthesis in Ehrlich ascites carcinoma cells and in some organs of healthy and tumor-bearing mice. Sikora E; Grzelakowska-Sztabert B Neoplasma; 1984; 31(2):139-48. PubMed ID: 6717683 [TBL] [Abstract][Full Text] [Related]
20. Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA Interference, on the activity of the new generation antifolate pemetrexed in HeLa cells. Chattopadhyay S; Wang Y; Zhao R; Goldman ID Clin Cancer Res; 2004 Dec; 10(23):7986-93. PubMed ID: 15585634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]